​To date, precision medicine therapeutics have mostly targeted extremely rare genetic diseases. But precision medicine clinical trials are now reaching more common adult-onset disorders, including neurodegenerative diseases. For example, more than 500 clinical trials have been conducted for Amyotrophic Lateral Sclerosis (ALS) - a number that is dwarfed by clinical research for Alzheimer’s disease. Despite the higher prevalence of these diseases however, patient identification and recruitment and post-market success challenges remain.

In this webinar, we’ll outline strategies to increase access to genetics services for rare disease patient populations and how sponsors can improve post-market success for precision medicine therapies. These strategies are applicable to other common, yet complex, diseases including age-related macular degeneration, cardiovascular disease, and multiple types of cancer.